Skip to main content
. 2016 Sep 21;8:475–484. doi: 10.2147/CEOR.S114524

Figure 3.

Figure 3

Cost-effectiveness plane (cost per QALY gained with GClb vs RClb).

Notes: Each point represents the ICER of each of the 1,000 simulations performed, comparing the new alternative (GClb) versus standard treatment (RClb).

Abbreviations: GClb, obinutuzumab + chlorambucil; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RClb, rituximab + chlorambucil.